127944-49-4

Upstream product

• 122225-12-1 (1'R,2'S,5S)-5-<<2'-<(tert-butyloxy)carbonyl>amino>-3'-cyclohexyl-1'-<(methoxyethoxy)methoxy>propyl>-3-ethyloxazolidin-2-one 
• 118219-12-8 <(3,4-cis-dihydroxypyrrolidino)carbonyl>-O-methyltyrosine 
• 143127-85-9 (S)-2-Amino-N-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethyl]-3-(3H-imidazol-4-yl)-propionamide 
• 122225-25-6 Boc-His amide of (1'R,2'S,5S)-5-<2'-amino-3'-cyclohexyl-1'-hydroxypropyl>-3-ethyloxazolidin-2-one 
• 118219-11-7 <(3,4-cis-dihydroxypyrrolidino)carbonyl>-O-methyltyrosine methyl ester 
• 119589-33-2 <(3-pyrrolinyl)carbonyl>-O-methyltyrosine methyl ester 
• 17791-52-5 (S)-2-tert-Butoxycarbonylamino-3-(3H-imidazol-4-yl)-propionic acid 
• 52177-38-5 α-isocyanato-L-O-methyltyrosine methyl ester 

Relevant academic research and scientific papers

Water-Soluble Renin Inhibitors: Design of a Subnanomolar Inhibitor with a Prolonged Duration of Action

Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility.This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys.While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability.Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointrestinal tract, extensive liver extraction severely limited bioavailability.